<DOC>
	<DOCNO>NCT00750139</DOCNO>
	<brief_summary>A research study compare safety effectiveness investigational medication call NAFT-500 placebo , use subject tinea pedis ( athlete 's foot ) .</brief_summary>
	<brief_title>Multicenter Study Safety Efficacy NAFT-500 Tinea Pedis</brief_title>
	<detailed_description>To evaluate efficacy safety NAFT-500 compare placebo treatment subject potassium hydroxide ( KOH ) culture positive symptomatic tinea pedis .</detailed_description>
	<mesh_term>Tinea</mesh_term>
	<mesh_term>Tinea Pedis</mesh_term>
	<criteria>1. Review sign statement Informed Consent HIPAA authorization . 2 . For minor ( less 18 year ) , parent/legal guardian must complete informed consent process AND subject must complete assent process sign appropriate form ( age appropriate ) . 3 . Males nonpregnant female â‰¥12 year age , race sex . Females childbearing potential must negative urine pregnancy test . 4 . Presence tinea pedis one foot characterize clinical evidence tinea infection ( least moderate erythema , moderate scaling , mild pruritus ) base sign symptom . 5 . KOH positive culture positive baseline skin scraping obtain site severely affect representative site overall severity . 6 . Subjects must good health free clinically significant disease might interfere study evaluation . 7 . Subject must able understand requirement study willing comply study requirement . 1 . A lifethreatening condition ( ex . autoimmune deficiency syndrome , cancer , unstable angina , myocardial infarction ) within last 6 month . 2 . Subjects abnormal finding physical laboratory consider investigator clinically important indicative condition might complicate interpretation study result . 3 . Subjects know hypersensitivity study medication component . 4 . Subjects recent history currently know abuse alcohol drug . 5 . Uncontrolled diabetes mellitus . 6 . Hemodialysis chronic ambulatory peritoneal dialysis therapy . 7 . Current diagnosis immunocompromising condition . 8 . Foot psoriasis , corn and/or callus involve web space , atopic contact dermatitis . 9 . Severe dermatophytoses , onychomycosis ( evaluated foot ) , mucocutaneous candidiasis , bacterial skin infection . 10 . Extremely severe tinea pedis ( incapacitate ) . 11 . Female subject pregnant lactating , use agree use acceptable form contraception study , intend become pregnant study ( female surgically sterilize post menopausal least 2 year consider childbearing potential ) .For purpose study , acceptable form birth control include : oral contraceptive , contraceptive patches/implants , double barrier method ( e.g. , use condom spermicide ) , IUD , abstinence second acceptable method subject become sexually active . 12 . Subjects use follow medication : Topical antifungal therapy , foot/shoe powder , topical corticosteroid apply foot within 14 day prior randomization . Topical terbinafine , butenafine , naftifine within 30 day prior randomization Oral antifungal therapy 3 month ( 8 month oral terbinafine ) prior randomization Systemic antibiotic corticosteroid treatment within 30 day randomization Any significant treatment , except hormonal contraception multivitamin , discretion investigator would interfere study treatment . Investigational drug within 30 day randomization</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Tinea Pedis</keyword>
	<keyword>Athlete 's foot</keyword>
</DOC>